|1.||Thiemermann, Christoph: 7 articles (05/2005 - 01/2002)|
|2.||Cuzzocrea, Salvatore: 7 articles (05/2005 - 01/2002)|
|3.||Threadgill, Michael D: 5 articles (01/2015 - 02/2004)|
|4.||Genovese, Tiziana: 4 articles (05/2005 - 05/2004)|
|5.||Mazzon, Emanuela: 4 articles (05/2005 - 01/2002)|
|6.||Muià, Carmelo: 3 articles (05/2005 - 12/2004)|
|7.||Di Paola, Rosanna: 3 articles (05/2005 - 05/2004)|
|8.||Caputi, Achille P: 3 articles (05/2005 - 01/2002)|
|9.||McDonald, Michelle C: 3 articles (02/2004 - 01/2002)|
|10.||Ahmad, Sheikh Fayaz: 2 articles (02/2015 - 08/2014)|
05/25/2004 - "Treatment of rats with 5-AIQ (3 mg/kg i.v.), attenuated the fall of mean arterial blood pressure caused by splanchnic artery occlusion shock. "
10/01/2006 - "In the present setting of shock/resuscitation in male rats the PARP inhibitor 5-AIQ proved to be very effective in ameliorating compromised liver microcirculation and function. "
05/25/2004 - "The aim of the present study was to investigate the effects of 5-aminoisoquinolinone (5-AIQ), a potent water-soluble inhibitor of poly(ADP-ribose) polymerase (PARP), in the pathogenesis of splanchnic artery occlusion shock. "
06/01/2000 - "Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock."
10/01/2006 - "5-AIQ treatment attenuated shock/resuscitation-induced increase of intrahepatic leukocyte-endothelial cell interaction with a marked reduction of both sinusoidal leukostasis and venular leukocyte adherence. "
02/01/2004 - "PARP inhibition with 5-AIQ during hepatic ischemia-reperfusion attenuates microvascular injury and reduces the extent of necrotic/apoptotic cell damage but does not protect from oxidative injury and does not improve postoperative survival rate."
02/01/2004 - "5-AIQ treatment attenuated ischemia-reperfusion-induced increases in the numbers of adherent platelets and leukocytes as well as of necrotic and apoptotic cells and ameliorated perfusion failure. "
02/01/2004 - "In in vivo experiments, anesthetized male Wistar rats were subjected to renal bilateral ischemia (45 minutes) followed by reperfusion (6 hours) in the absence or presence of 5-AIQ (0.3 mg/kg) after which renal dysfunction, injury and PARP activation were assessed. "
02/01/2004 - "5-Aminoisoquinolinone reduces renal injury and dysfunction caused by experimental ischemia/reperfusion."
11/01/2002 - "The novel PARP inhibitor 5-aminoisoquinolinone reduces the liver injury caused by ischemia and reperfusion in the rat."
10/01/2013 - "Compared to the 5-AIQ and ZN groups, there was no notable difference in the LDH, MDA, TOS, TAS and hemodynamic parameters of the 5-AIQ+ZN group, but myocardial infarct size decreased significantly, as determined by volume and weight measurements. "
10/26/2001 - "Administration (1 min before reperfusion) of 5-aminoisoquinolinone reduced myocardial infarct size in a dose-related fashion. "
10/01/2013 - "These results show that the combined use of Zoniporide and 5-Aminoisoquinolinone provides increased protection against I/R injury by reducing myocardial infarct size. "
10/26/2001 - "Thus, 5-aminoisoquinolinone is a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase activity in cardiac myoblasts and reduces myocardial infarct size in vivo."
10/26/2001 - "5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size."
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/01/2002 - "This study was designed to investigate the effects of 5-aminoisoquinolinone (5-AIQ), a water-soluble potent inhibitor of poly-(ADP-ribose) polymerase (PARP) in a rat model of liver ischemia-reperfusion injury. "
10/01/2013 - "Investigating the effect of the poly(ADP-ribose) polymerase inhibitor 5-aminoisoquinolinone and the Na⁺-H⁺ exchanger inhibitor zoniporide on isolated perfused rat hearts during ischemia-reperfusion injury."
|1.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|2.||(1- (quinolin- 5- yl)- 5- cyclopropyl- 1H- pyrazole- 4- carbonyl)guanidine
|5.||Interleukin-17 (Interleukin 27)
|6.||NF-kappa B (NF-kB)
|7.||Messenger RNA (mRNA)
|8.||Poly Adenosine Diphosphate Ribose